Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$41.44
+0.6%
$41.71
$22.11
$53.18
$2.32B1.6843,987 shs19,220 shs
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$1.85
-3.6%
$2.43
$1.62
$4.27
$75.52M0.3913,911 shs1,837 shs
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$33.97
$33.70
$20.35
$34.38
$1.50B0.23973,737 shsN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.75
+1.9%
$0.82
$0.55
$2.00
$61.55M1.26214,329 shs96,001 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-2.37%+4.73%+3.70%+9.83%+24.39%
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%+2.56%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-3.65%-3.14%-24.49%-42.55%+2.21%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.00%0.00%0.00%0.00%0.00%
VolitionRx Limited stock logo
VNRX
VolitionRx
+2.22%-15.01%+0.84%-37.63%+73,599,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.7906 of 5 stars
3.41.00.00.02.40.00.0
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.2127 of 5 stars
0.03.00.00.00.60.81.3
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
1.3493 of 5 stars
3.50.00.00.02.90.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.80
Moderate Buy$66.0059.27% Upside
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
2.00
HoldN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$2.50233.33% Upside

Current Analyst Ratings

Latest HSKA, VIVO, CLDX, TKNO, and VNRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
4/17/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
3/27/2024
VolitionRx Limited stock logo
VNRX
VolitionRx
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$2.50
3/22/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
3/12/2024
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
2/27/2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$72.00 ➝ $90.00
(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$6.88M336.70N/AN/A$9.08 per share4.56
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$36.68M2.06N/AN/A$2.21 per share0.84
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$333.02M4.49$1.78 per share19.13$8.41 per share4.04
VolitionRx Limited stock logo
VNRX
VolitionRx
$770K79.94N/AN/A($0.11) per share-6.82

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$141.43M-$2.91N/AN/AN/A-2,054.46%-41.06%-37.65%8/13/2024 (Estimated)
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$36.78M-$1.16N/AN/AN/A-100.26%-38.12%-25.95%5/13/2024 (Confirmed)
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
$42.46M$0.9735.02N/A12.70%16.74%13.09%N/A
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.51N/AN/A-4,557.29%N/A-154.24%N/A

Latest HSKA, VIVO, CLDX, TKNO, and VNRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2024N/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/AN/A  
3/25/2024N/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A-$0.11-$0.11-$0.11$0.50 million$0.24 million    
3/11/2024Q4 2023
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.23-$0.22+$0.01-$0.18$8.20 million$7.87 million
2/26/2024Q4 2023
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.76-$0.57+$0.19-$0.31$1.20 million$4.13 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
13.87
13.87
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.15
5.14
3.84
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
0.07
3.63
2.46
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.69
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Heska Co. stock logo
HSKA
Heska
99.01%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
89.72%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3.70%
Heska Co. stock logo
HSKA
Heska
12.30%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
15.20%
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
2.30%
VolitionRx Limited stock logo
VNRX
VolitionRx
15.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
16055.90 million53.83 millionOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
21040.82 million34.62 millionNot Optionable
Meridian Bioscience, Inc. stock logo
VIVO
Meridian Bioscience
70244.01 million43.00 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
11082.07 million69.43 millionOptionable

HSKA, VIVO, CLDX, TKNO, and VNRX Headlines

SourceHeadline
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business UpdateVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
prnewswire.com - May 8 at 8:00 AM
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.comVolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com
americanbankingnews.com - May 4 at 2:38 AM
Research Analysts Set Expectations for VolitionRx Limiteds FY2024 Earnings (NYSE:VNRX)Research Analysts Set Expectations for VolitionRx Limited's FY2024 Earnings (NYSE:VNRX)
marketbeat.com - April 10 at 8:28 AM
VolitionRx Limited Forecasted to Post Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX)VolitionRx Limited Forecasted to Post Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX)
marketbeat.com - April 9 at 6:09 AM
VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...
msn.com - April 8 at 3:37 PM
VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for SepsisVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for Sepsis
finance.yahoo.com - April 8 at 3:37 PM
VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023
msn.com - March 25 at 9:15 PM
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business UpdateVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
prnewswire.com - March 25 at 4:10 PM
Earnings Outlook For VolitionRXEarnings Outlook For VolitionRX
benzinga.com - March 22 at 11:30 AM
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business UpdateVolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
prnewswire.com - March 21 at 8:30 AM
VolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical OfficerVolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical Officer
finanznachrichten.de - March 21 at 5:25 AM
VolitionRx Names Andrew Retter Chief Medical OfficerVolitionRx Names Andrew Retter Chief Medical Officer
markets.businessinsider.com - March 19 at 11:18 PM
Volition appoints Dr Andrew Retter as Chief Medical OfficerVolition appoints Dr Andrew Retter as Chief Medical Officer
finance.yahoo.com - March 19 at 6:17 PM
VolitionRX LtdVolitionRX Ltd
money.usnews.com - March 19 at 8:16 AM
VolitionRX Stock (AMEX:VNRX), Short Interest ReportVolitionRX Stock (AMEX:VNRX), Short Interest Report
benzinga.com - February 22 at 10:12 PM
VolitionRx stock soars after company discloses $13M in milestone paymentsVolitionRx stock soars after company discloses $13M in milestone payments
msn.com - January 2 at 7:35 PM
VolitionRx milestone payment important step forward, says EF HuttonVolitionRx milestone payment 'important step forward,' says EF Hutton
realmoney.thestreet.com - January 2 at 7:35 PM
Analyzing VolitionRX Ltd (VNRX) After Recent Trading ActivityAnalyzing VolitionRX Ltd (VNRX) After Recent Trading Activity
knoxdaily.com - January 1 at 7:42 AM
Volition Presents at the 5th Annual Congress of the International Liquid Biopsy SocietyVolition Presents at the 5th Annual Congress of the International Liquid Biopsy Society
finance.yahoo.com - November 17 at 1:08 PM
VolitionRx to host Q3 earnings call on November 15VolitionRx to host Q3 earnings call on November 15
proactiveinvestors.com - November 8 at 2:08 PM
VolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s PerspectiveVolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s Perspective
markets.businessinsider.com - October 28 at 11:59 PM
A company insider recently bought 5,000 shares of VolitionRX Ltd [VNRX]. Should You Buy?A company insider recently bought 5,000 shares of VolitionRX Ltd [VNRX]. Should You Buy?
knoxdaily.com - October 20 at 1:29 PM
A Guide To The Risks Of Investing In VolitionRX Ltd (VNRX)A Guide To The Risks Of Investing In VolitionRX Ltd (VNRX)
knoxdaily.com - September 25 at 8:07 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Celldex Therapeutics logo

Celldex Therapeutics

NASDAQ:CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Heska logo

Heska

NASDAQ:HSKA
Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.
Alpha Teknova logo

Alpha Teknova

NASDAQ:TKNO
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Meridian Bioscience logo

Meridian Bioscience

NASDAQ:VIVO
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
VolitionRx logo

VolitionRx

NYSE:VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.